Meer informatie

Artikelen:

  • Siddiqi L, Joles JA, Grassi G and Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens 2009; 27: 1341-1349.
  • Nadery-Siddiqi L, Mali WP, Blankestijn PJ. Hypertensiebehandeling met percutane endovasculaire renale denervatie. Ned Tijdschr Geneeskd. 2010;154:A 2165.
  • Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
  • Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917
  • Schlaich MP, Sobotka PA, Krum H, Lambert E and Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934.
  • Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE and Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909
  • Blankestijn PJ, Ritz E. Renal denervation: potential impact on hypertension in kidney disease? Nephrol Dial Transplant 2011
  • Voskuil, M., Verloop, W. L., Blankestijn, P. J., Agostoni, P., Stella, P. R., and Doevendans, P. A. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth.Heart J. 2011; epub ahead of print.

Internet:

http://ardian.com/ous/medical-professionals/index.shtml